Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is investigating reports that more patients are experiencing serious bleeding events after taking Boehringer Ingelheim GmbH’s Pradaxa (dabigatran) than anticipated based on clinical trial results.